Search
Search
About
Log in
Join
Experiences with
Venetoclax
Posts
Communities
1,018 public posts
Filter results
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Update on The CLARITY Study
CLARITY is a phase II trial that combined ibrutinib with
venetoclax
in patients with relapsed or refractory CLL. The primary end point was eradication of MRD after 12 months of combined therapy.
CLARITY is a phase II trial that combined ibrutinib with
venetoclax
in patients with relapsed or refractory CLL. The primary end point was eradication of MRD after 12 months of combined therapy.
Jm954
Administrator
in
CLL Support
5 years ago
Shingles always a concern with CLL
Anyway my shingles may have recurred right before my treatment 4 of Gazyva in the G plus
Venetoclax
protocol. On my face developed a large weeping hive My dermatologist doubled my dose of acyclovir from 500 mg per day to 1 g. So it’s already resolving . Only pot hole in the road .
Anyway my shingles may have recurred right before my treatment 4 of Gazyva in the G plus
Venetoclax
protocol. On my face developed a large weeping hive My dermatologist doubled my dose of acyclovir from 500 mg per day to 1 g. So it’s already resolving . Only pot hole in the road .
LovecuresCLL
in
CLL Support
5 years ago
Change of treatment from ibrutanib to Venetoclax. Progression of CLL?
The doctor is going to put him on
Venetoclax
. She has also prescribed steroids as he has been getting breathless. It's been quite a blow and I'm posting this in the hope that someone may have experienced the same and it turned out to be for the better. But also to ask opinions on
Venetoclax
.
The doctor is going to put him on
Venetoclax
. She has also prescribed steroids as he has been getting breathless. It's been quite a blow and I'm posting this in the hope that someone may have experienced the same and it turned out to be for the better. But also to ask opinions on
Venetoclax
.
Poohey
in
CLL Support
5 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Factors affecting pricing for Ibrutinib and Venetoclax
The gaming of the US Patent system by Big Pharma makes critical drugs very expensive. https://www.axios.com/big-pharma-abbvie-humira-patents-mergers-6345f5cc-0d23-4fdd-bd1b-1965d3758ae4.html
The gaming of the US Patent system by Big Pharma makes critical drugs very expensive. https://www.axios.com/big-pharma-abbvie-humira-patents-mergers-6345f5cc-0d23-4fdd-bd1b-1965d3758ae4.html
Indolent
in
CLL Support
5 years ago
Is 400 mg of venetoclax always better?
That is, they can’t tolerate 400 mg of
venetoclax
. However, they seem to do fine on 200 mg or even 100 mg including ALC under 1.
That is, they can’t tolerate 400 mg of
venetoclax
. However, they seem to do fine on 200 mg or even 100 mg including ALC under 1.
profrich
in
CLL Support
5 years ago
ALC Dropping Fast
I shifted from Imbruvica to
Venetoclax
because Imbruvica was showing signs it was failing and my ALC was rising. Also, I had an Afib event and had cardioversion to get back in rhythm. Even before I reached full dose of
Venetoclax
my white count and ALC were falling fast.
I shifted from Imbruvica to
Venetoclax
because Imbruvica was showing signs it was failing and my ALC was rising. Also, I had an Afib event and had cardioversion to get back in rhythm. Even before I reached full dose of
Venetoclax
my white count and ALC were falling fast.
Fant1924
in
CLL Support
5 years ago
Anyone taking 100 mg of acalabrutinib?
I switched from acalabrutinib to
venetoclax
. Now I plan to take both. I want to only take 100 mg of acalabrutinib to minimize side effects. Is anyone doing well on that dosage?
I switched from acalabrutinib to
venetoclax
. Now I plan to take both. I want to only take 100 mg of acalabrutinib to minimize side effects. Is anyone doing well on that dosage?
profrich
in
CLL Support
5 years ago
Remission over .... venetoclax (&R) here we come
His consultant has recommended
venetoclax
(2years) and rituximab (6 months) starting in September. We are so grateful to the researchers and our wonderful NHS that this is an option.
His consultant has recommended
venetoclax
(2years) and rituximab (6 months) starting in September. We are so grateful to the researchers and our wonderful NHS that this is an option.
Fowey2009
in
CLL Support
5 years ago
Clinical trial results & reviews of new treatments for CLL written in easy to understand terms
id=31288 - Here is a sample of the Ibrutinib and
Venetoclax
write up: [i] Combining ibrutinib and
venetoclax
for first-time treatment of chronic lymphocytic leukemia - In a nutshell This study wanted to research if the combination therapy of ibrutinib (Imbruvica) and
venetoclax
(Venclexta) was effective
id=31288 - Here is a sample of the Ibrutinib and
Venetoclax
write up: [i] Combining ibrutinib and
venetoclax
for first-time treatment of chronic lymphocytic leukemia - In a nutshell This study wanted to research if the combination therapy of ibrutinib (Imbruvica) and
venetoclax
(Venclexta) was effective
lankisterguy
Volunteer
in
CLL Support
5 years ago
Dr. Shadman on Fixed Durations of Treatment in CLL
However, this is not a guarantee because studies, such as CLL14 or MURANO, were designed to give
venetoclax
(Venclexta) in combination with a CD20-targeted antibody for 1 and 2 years, respectively. It is not yet known what happens after these patients stop treatment.
However, this is not a guarantee because studies, such as CLL14 or MURANO, were designed to give
venetoclax
(Venclexta) in combination with a CD20-targeted antibody for 1 and 2 years, respectively. It is not yet known what happens after these patients stop treatment.
Jm954
Administrator
in
CLL Support
5 years ago
Article in NEJM on Venetoclax & Obinutuzumab
Here is an article that was just received from the New England Journal of Medicine that some may find of interest. Jack O. https://www.nejm.org/doi/full/10.1056/NEJMoa1815281?query=oncology-hematology
Here is an article that was just received from the New England Journal of Medicine that some may find of interest. Jack O. https://www.nejm.org/doi/full/10.1056/NEJMoa1815281?query=oncology-hematology
jdolinger
in
CLL Support
5 years ago
Issues After Imbruvica
Venetoclax
400 mg was added in July of 2017 as a ramp up. I continued on the Imbruvica/
Venetoclax
trial with no issues until May of 2018 when I had an Afib episode. After the 2nd episode a month later, I was reduced to 2 140mg of Imbruvica along with the 400 mg of
Venetoclax
.
Venetoclax
400 mg was added in July of 2017 as a ramp up. I continued on the Imbruvica/
Venetoclax
trial with no issues until May of 2018 when I had an Afib episode. After the 2nd episode a month later, I was reduced to 2 140mg of Imbruvica along with the 400 mg of
Venetoclax
.
Louie_CC
in
CLL Support
5 years ago
ASH 2018: Dr. Lindsey Roeker, on real world use of venetoclax for CLL (chronic lymphocytic leukemia)
Is
venetoclax
as safe and effective in the real world as compared to clinical trials? Read my ASH interview with Dr. Roeker to get the comforting news: https://cllsociety.org/2019/06/ash-2018-dr-lindsey-roeker-on-real-world-use-of-
venetoclax
-for-cll-chronic-lymphocytic-leukemia/
Is
venetoclax
as safe and effective in the real world as compared to clinical trials? Read my ASH interview with Dr. Roeker to get the comforting news: https://cllsociety.org/2019/06/ash-2018-dr-lindsey-roeker-on-real-world-use-of-
venetoclax
-for-cll-chronic-lymphocytic-leukemia/
bkoffman
CLL CURE Hero
in
CLL Support
5 years ago
Venetoclax for CLL patients who progress after MORE THAN ONE B‐cell receptor pathway inhibitor
. >1 prior BCRi, [u]
these data support the earlier use of
[/u] in the treatment paradigm to optimize response, though
venetoclax
was still active in this poor‐risk group of patients who had received >1 prior BCRi.
. >1 prior BCRi, [u]
these data support the earlier use of
[/u] in the treatment paradigm to optimize response, though
venetoclax
was still active in this poor‐risk group of patients who had received >1 prior BCRi.
Jm954
Administrator
in
CLL Support
5 years ago
Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
In the future, combination with new drugs such as ibrutinib,
venetoclax
, and idelalisib, and sequential infusion of CAR-T cells targeting multiple antigens like CD19, CD23, and FcμR may be the trend of CAR-T therapy for CLL.
In the future, combination with new drugs such as ibrutinib,
venetoclax
, and idelalisib, and sequential infusion of CAR-T cells targeting multiple antigens like CD19, CD23, and FcμR may be the trend of CAR-T therapy for CLL.
Jm954
Administrator
in
CLL Support
5 years ago
Efficacy of venetoclax monotherapy in patients with relapsed CLL in the post‐BCR inhibitor setting: a UK wide analysis
Feb 2019
Venetoclax
is a BCL2 inhibitor with activity in relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL). We conducted a multi‐centre retrospective analysis of 105 R/R CLL patients who received
venetoclax
pre‐National Health Service commissioning.
Feb 2019
Venetoclax
is a BCL2 inhibitor with activity in relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL). We conducted a multi‐centre retrospective analysis of 105 R/R CLL patients who received
venetoclax
pre‐National Health Service commissioning.
Jm954
Administrator
in
CLL Support
5 years ago
ASH 2018: Dr. Lindsey Roeker research from ASH 2018 on real world use of venetoclax for CLL
Lindsey Roeker research from ASH 2018 on real world use of
venetoclax
for CLL: Turns out
venetoclax
works as well in the community as not does in trial: For more see: https://cllsociety.org/2019/06/ash-2018-dr-lindsey-roeker-on-real-world-use-of-
venetoclax
-for-cll-chronic-lymphocytic-leukemia/ Stay strong
Lindsey Roeker research from ASH 2018 on real world use of
venetoclax
for CLL: Turns out
venetoclax
works as well in the community as not does in trial: For more see: https://cllsociety.org/2019/06/ash-2018-dr-lindsey-roeker-on-real-world-use-of-
venetoclax
-for-cll-chronic-lymphocytic-leukemia/ Stay strong
bkoffman
CLL CURE Hero
in
CLL Support
5 years ago
MRD-U Baby your one of four in two million!
You can see now why they are getting so excited about the MRD status’s we we seeing now in
venetoclax
since it would seem likely they will follow similar patterns seen with FCR induced MRD-U over the next few years.
You can see now why they are getting so excited about the MRD status’s we we seeing now in
venetoclax
since it would seem likely they will follow similar patterns seen with FCR induced MRD-U over the next few years.
AdrianUK
in
CLL Support
5 years ago
42% of patients achieved U-MRD6 with venetoclax + obinutuzumab!
From German CLL14 study, presented at IMCL 2019. source: https://twitter.com/anthonymatomd/status/1141680121646145541 overview of UMRD-6: https://healthunlocked.com/cllsupport/posts/139267149/u-mrd6-is-the-new-mrd
From German CLL14 study, presented at IMCL 2019. source: https://twitter.com/anthonymatomd/status/1141680121646145541 overview of UMRD-6: https://healthunlocked.com/cllsupport/posts/139267149/u-mrd6-is-the-new-mrd
avzuclav
in
CLL Support
5 years ago
With a CLL diagnosis, knowing more about your immune system could save your life!
private/147136898/cll-patients-what-is-shingles
Skin Conditions (from Patient Power)
Covers skin cancer, hives, hair loss and texture changes, nail changes and fissuring of fingertips and bruising with BTK inhibitors, (acalabrutinib, ibrutinib, zanubrutinib, etc), skin dryness and neuropathy with
venetoclax
private/147136898/cll-patients-what-is-shingles
Skin Conditions (from Patient Power)
Covers skin cancer, hives, hair loss and texture changes, nail changes and fissuring of fingertips and bruising with BTK inhibitors, (acalabrutinib, ibrutinib, zanubrutinib, etc), skin dryness and neuropathy with
venetoclax
AussieNeil
Partner
in
CLL Support
5 years ago
1
...
35
36
37
...
51
Next page
10
20
30
40
50
Filter results
Clear filters
Posted in
All communities
CLL Support
972 results
CLL America Support
24 results
Leukaemia Support
10 results
View top 10 communities
Sort by
Most Relevant
Newest